The Alzheimer's Disease Cooperative Study (ADCS) is a leading brand at the forefront of Alzheimer's disease (AD) research and treatment efforts. Founded by the late Leon Thal, MD, a renowned Alzheimer's researcher, the ADCS aims to discover, develop, and test new drugs for the treatment of AD. As part of the UC San Diego's AD research and treatment initiative, the ADCS collaborates with the Shiley-Marcos Alzheimer's Disease Research Center.

Since its formation in 1991, the ADCS has been instrumental in advancing AD research by initiating 30 research studies, including drug studies and instrument development protocols. These studies have involved participation from 9 to 800 individuals, contributing to groundbreaking publications. Some notable achievements of the ADCS include the development of new assessment tools for AD patients, standardization of clinical rating scales, and protocol testing of various agents to delay disease progression.

The ADCS actively evaluates compounds that have the potential to benefit AD patients, including those without patent protection or marketed for other medical needs. They focus on improving cognition, slowing decline, and ameliorating behavioral symptoms. Moreover, the ADCS places an emphasis on expanding the diversity of participants in AD clinical research.

Through their dedication, the ADCS has significantly contributed to the advancement of AD research and treatment, sharing their assessment tools, trial methods, and data with academic investigators and commercial entities globally. For those interested in their services or seeking to support their cause, ADCS can be contacted via email or phone. Their commitment to finding effective treatments for AD remains unwavering